Literature DB >> 20837136

E2F1 inhibits MDM2 expression in a p53-dependent manner.

Xu Tian1, Youjun Chen, Wanglai Hu, Mian Wu.   

Abstract

MDM2 expression is down-regulated upon E2F1 over-expression, but the mechanism is not well defined. In the current study, we found that E2F1 inhibits MDM2 expression by suppressing its promoter activity. Although E2F1 binds to the MDM2 promoter, the inhibitory effect of E2F1 on the MDM2 promoter does not require the direct binding. We demonstrate that E2F1 inhibits MDM2 promoter activity in a p53-dependent manner. Knockdown of p53 in U2OS cells impairs the inhibitory effect of E2F1 on the MDM2 promoter. Consistent with this observation, E2F1 does not inhibit MDM2 promoter activity in p53-deficient H1299 cells, and the inhibition is restored when p53 is expressed exogenously. Both E2F1 and p53 are up-regulated after DNA damage stimulation. We show that such stimulation induces E2F1 to inhibit MDM2 promoter activity and promote p53 accumulation. Furthermore, inhibition of MDM2 by E2F1 promotes E2F1 induced apoptosis. These data suggest that E2F1 regulates the MDM2-p53 pathway by inhibiting p53 induced up-regulation of MDM2.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837136     DOI: 10.1016/j.cellsig.2010.09.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

Review 1.  The regulation of MDM2 oncogene and its impact on human cancers.

Authors:  Yuhan Zhao; Haiyang Yu; Wenwei Hu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2014-01-03       Impact factor: 3.848

2.  The Many Faces of MDM2 Binding Partners.

Authors:  Maurisa F Riley; Guillermina Lozano
Journal:  Genes Cancer       Date:  2012-03

3.  Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.

Authors:  Benjamin Gottschalk; Andreas Klein
Journal:  Mol Cell Biochem       Date:  2013-04-07       Impact factor: 3.396

Review 4.  Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.

Authors:  Jesús Hernández-Monge; Adriana Berenice Rousset-Roman; Ixaura Medina-Medina; Vanesa Olivares-Illana
Journal:  Genes Cancer       Date:  2016-09

5.  Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia.

Authors:  P Gravells; L Hoh; S Solovieva; A Patil; E Dudziec; I G Rennie; K Sisley; H E Bryant
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

6.  Long non-coding RNA H19 regulates E2F1 expression by competitively sponging endogenous miR-29a-3p in clear cell renal cell carcinoma.

Authors:  Haowei He; Nana Wang; Xiaoming Yi; Chaopeng Tang; Dong Wang
Journal:  Cell Biosci       Date:  2017-12-01       Impact factor: 7.133

Review 7.  EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers.

Authors:  Joanna B Wilson; Evelyne Manet; Henri Gruffat; Pierre Busson; Marc Blondel; Robin Fahraeus
Journal:  Cancers (Basel)       Date:  2018-04-06       Impact factor: 6.639

8.  Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.

Authors:  Sana AlQarni; Yazeed Al-Sheikh; Donald Campbell; Mark Drotar; Adele Hannigan; Shelagh Boyle; Pawel Herzyk; Andrew Kossenkov; Kate Armfield; Lauren Jamieson; Mariarca Bailo; Paul M Lieberman; Penelope Tsimbouri; Joanna B Wilson
Journal:  Oncogene       Date:  2018-04-25       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.